Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Key facts

Sponsor

The Affiliated People's Hospital of Ningbo University

Principal Investigator

Ying Lu

The Affiliated People's Hospital of Ningbo University

Intervention

Etoposide(drug)

Enrollment

99 enrolled

Eligibility

18-75 years · All sexes

Timeline

2024 – 2026

Study locations (16)

• Dongyang People's Hospital, Dongyang, Zhejiang, China
• The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
• Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
• Huzhou central hospital, Huzhou, Zhejiang, China
• The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
• Jinhua Municipal Central Hospital, Jinhua, Zhejiang, China
• Jinhua People's Hospital, Jinhua, Zhejiang, China
• Lishui Central Hospital, Lishui, Zhejiang, China
• Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
• The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
• Shaoxing People's Hospital, Shaoxing, Zhejiang, China
• Shaoxing Second Hospital, Shaoxing, Zhejiang, China
• Taizhou Central Hospital, Taizhou, Zhejiang, China
• Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
• The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
• +1 more locations on ClinicalTrials.gov

Collaborators

First Affiliated Hospital of Zhejiang University · First Affiliated Hospital of Wenzhou Medical University · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · The Central Hospital of Lishui City · Jinhua People's Hospital · Shaoxing People's Hospital · Shaoxing Second Hospital · Zhejiang Provincial Tongde Hospital · Taizhou Hospital · Dongyang People's Hospital · Affiliated Hospital of Jiaxing University · Huizhou Municipal Central Hospital · Second Affiliated Hospital of Wenzhou Medical University · Ningbo Medical Center Lihuili Hospital · Jinhua Municipal Central Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07225738
  A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
  City of Hope Medical Center
• RECRUITINGPHASE3NCT06980480
  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
  Takeda
• RECRUITINGPHASE4NCT07094048
  Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
  CHU de Quebec-Universite Laval
• RECRUITINGNANCT07226934
  An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
  Washington University School of Medicine
• RECRUITINGEARLY PHASE1NCT07294625
  A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1NCT07179679
  A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
  Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• RECRUITINGPHASE3NCT06514508
  Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
  Guangzhou Gloria Biosciences Co., Ltd.
• RECRUITINGNANCT07359014
  Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Multiple myeloma →